Cediranib
作者：齐岳
发布时间：2023-08-23
09:15:55
点击数：
产品名称：Cediranib
产品描述：
| 产品描述 | Cediranib (AZD2171) is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro, also inhibits Flt1/4 (IC50: 5 nM/≤3 nM), similar activity against PDGFRβ and c-Kit, selective more for VEGFR than PDGFR-α (36-fold), CSF-1R (110-fold), and Flt3 (1000-fold) in HUVEC cells. |
| 靶点活性 | Flt1:5 nM, Flt4:≤3 nM |
| 体外活性 | Cediranib对人类移植瘤模型具有十分有效的作用且有剂量依赖性.此外,Cediranib可使人肺*移植瘤血管衰退.Cediranib使骨骼过度生长,对卵巢中黄体的产生具有阻碍作用,并抑制依赖于血管生成的生理程序. |
| 体内活性 | 在体外,Cediranib（微摩）可直接抑制细胞增殖。Cediranib（次纳摩）阻断细管产生,且对体内VEGF诱导的血管生成有抑制作用。Cediranib对bFGF（IC50：0.5 μM）和EGF（IC50：0.11 μM）有抑制作用。在MG63细胞系中,Cediranib抑制PDGF-AA（IC50：0.04 μM）。Cediranib抑制 Flt-1相关激酶（IC50：5 nM）,还对VEGF-C和VEGF-D受体Flt-4有抑制作用（IC50<3 nM）。此外,Cediranib对c-Kit（IC50：2 nM）和PDGFR-β（IC50：5 nM）酪氨酸激酶有抑制作用。 |
| 激酶实验 | Kinase inhibition: Cediranib is dissolved in DMSO at a concentration of 10 mM. All enzyme assays are run at, or just below, the respective Km for ATP (0.2 - 30 μM). The inhibitory activity of Cediranib is determined against a range of recombinant tyrosine kinases [KDR, Flt-1, Flt-4, c-Kit, PDGFRα, PDGFRβ, CSF-1R, Flt-3, FGFR1, Src, Abl, epidermal growth factor receptor (EGFR), ErbB2, Aurora A, and Aurora B] using ELISA. Selectivity versus CDK2 and CDK4 serine/threonine kinases is examined using scintillation proximity assays with a retinoblastoma substrate and [γ-sup>33P]ATP. Activity of Cediranib is compared to MAPK kinase (MEK), which shows dual specificity. It is determined using a MAPK substrate, [γ-33P]ATP, and paper capture/scintillation counting. |
| 细胞实验 | The proliferation of the HUVEC cell line is evaluated in the presence and absence of growth factors by measuring 3H-thymidine incorporation following a 4-day incubation period. Proliferation of MG63 osteosarcoma cells is induced by PDGF-AA, which selectively activates signaling of the PDGFRα homodimer. HUVEC and MG63 osteosarcoma cells are cultured in DMEM without phenol red containing 1% charcoal stripped FCS, 2 mM glutamine, and 1% nonessential amino acids for 24 hours. Cediranib or vehicle is added with PDGF-AA ligand (50 ng/mL) and plates incubated for another 72 hours. Cellular proliferation is determined using bromodeoxyuridine ELISA. (Only for Reference) |
| 别名 | AZD2171, NSC-732208, 西地尼布 |
| 分子量 | 450.514 |
| 分子式 | C25H27FN4O3 |
| CAS No. | 288383-20-0 |
存储
Powder: -20°C for 3 years | In solvent: -80°C for 2 years
溶解度
H2O: <1 mg/mL
DMSO: 83 mg/mL (184.2 mM)
Ethanol: <1 mg/mL
( < 1 mg/mL refers to the product slightly soluble or insoluble )
联系我们：
邮箱：2519696869@qq.com
QQ: 2519696869
电话：18066853083
微信：18066853083
公司介绍：
西安齐岳生物科技有限公司是集化学科研和定制与一体的高科技化学公司。业务范围包括化学试剂和产品的研发、生产、销售等。涉及产品为通用试剂的分销、非通用试剂的定制与研发，涵盖生物科技、化学品、中间体和化工材料等领域。
主营产品：COF、MOF单体系列：三蝶烯衍生物、金刚烷衍生物、四苯甲烷衍生物、peg、上转换、石墨烯、光电材料、点击化学、凝集素、载玻片、蛋白质交联剂、脂质体、蛋白、多肽、氨基酸、糖化学等。
